Systemic therapeutic strategies for GEP-NETS: What can we expect in the future?

Cancer and Metastasis Reviews

Volumn 33, Issue 1, 2014, Pages 367-372

  Raymond, E ^a   Garcia Carbonero R ^b   Wiedenmann, B ^c   Grande, E ^d   Pavel, M ^c  

^a BEAUJON HOSPITAL   (France)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Angiogenesis; Carcinoid; Drug combination; Drug resistance; Everolimus; mTOR; Pancreatic neuroendocrine tumors; PDGFR; Personalized medicine; Rapamycin; Sequencial therapy; Somatostatin analogues; Sunitinib; Temozolomide; Temsirolimus; VEGFR

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ATM PROTEIN; AXITINIB; BEVACIZUMAB; BUPARLISIB; CABOZANTINIB; CAPECITABINE; DACTOLISIB; DANUSERTIB; EVEROLIMUS; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; PASIREOTIDE; PAZOPANIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SORAFENIB; SUNITINIB; TELOTRISTAT ETHYL; TEMOZOLOMIDE; TEMSIROLIMUS; ANTINEOPLASTIC AGENT;

ALPHA THALASSEMIA; ANGIOGENESIS; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GENE SEQUENCE; HUMAN; MAINTENANCE THERAPY; MEDICAL SPECIALIST; MONOTHERAPY; PATIENT SELECTION; PRIORITY JOURNAL; REMISSION; SYSTEMIC THERAPY; TUMOR BIOPSY; TUMOR GROWTH; X LINKED MENTAL RETARDATION; DRUG EFFECTS; FORECASTING; GENETICS; INTESTINAL NEOPLASMS; MOLECULARLY TARGETED THERAPY; MUTATION; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROCEDURES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TRENDS;

ANTINEOPLASTIC AGENTS; FORECASTING; HUMANS; INTESTINAL NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84899936180     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9467-z     Document Type: Article

References (26)

1. Corbo, V., et al. (2012). Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Annals of Oncology, 23, 127-134.
2. Corbo, V., et al. (2010). MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocrine-Related Cancer, 17, 771-783.
3. Jiao, Y., et al. (2011). DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science, 331, 1199-1203.
4. Missiaglia, E., et al. (2010). Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. Journal of Clinical Oncology, 28, 245-255.
5. Faivre, S., Sablin, M. P., Dreyer, C., & Raymond, E. (2010). Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America, 39, 811-826.
6. Couvelard, A., et al. (2005). Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. British Journal of Cancer, 92, 94-101.
7. Rinke, A., et al. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology, 27, 4656-4663.
8. Raymond, E., et al. (2011). Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. The New England Journal of Medicine, 364, 501-513.
9. Yao, J. C., et al. (2011). Everolimus for advanced pancreatic neuroendocrine tumors. The New England Journal of Medicine, 364, 514-523.
10. Ekeblad, S., et al. (2007). Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clinical Cancer Research, 13, 2986-2991.
11. Kulke, M. H., et al. (2009). O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clinical Cancer Research, 15, 338-345.
12. Strosberg, J. R., et al. (2011). First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 117, 268-275.
13. Tijeras-Raballand, A., et al. (2012). Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. Targeted Oncology, 7, 173-181.
14. Maira, S. M., et al. (2008). Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics, 7, 1851-1863.
15. Fraedrich, K., et al. (2012). Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model. Clinical Cancer Research, 18, 4621-4632.
16. Fendrich, V., et al. (2011). Hedgehog inhibition with cyclopamine represses tumor growth and prolongs survival in a transgenic mouse model of islet cell tumors. Annals of Surgery, 253, 546-552.
17. Waser, B., et al. (2012). Glucose- dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors. Journal of Clinical Endocrinology and Metabolism, 97, 482-488.
18. O'Dorisio, B., et al. (2012) Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a double-blind, placebo-controlled multicenter study. Journal Clinical Oncology, 30, suppl; abstr 4085.
19. Sennino, B., et al. (2012). Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discovery, 2, 270-287.
20. Yap, T. A., et al. (2008). Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Current Opinion in Pharmacology, 8, 393-412.
21. Serra, V., et al. (2008). NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Research, 68, 8022-8030.
22. Schnell, C. R., et al. (2008). Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Research, 68, 6598-6607.
23. Pavel, M. (2013). Translation of molecular pathways into clinical trials of neuroendocrine tumors. Neuroendocrinology, 97(1), 99-112.
24. Chiu, C. W., Nozawa, H., & Hanahan, D. (2010). Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. Journal of Clinical Oncology, 28, 4425-4433.
25. Niraula, S., et al. (2012). The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. Journal of Clinical Oncology, 30, 3012-3019.
26. Schutz, F. A., Je, Y., Richards, C. J., & Choueiri, T. K. (2012). Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. Journal of Clinical Oncology, 30, 871-877.